There were a few rocky months for Novo Nordisk.
Prescription data from IQVIA suggests Eli Lilly. The potential successor of Wegovy, Cagrisema, had the expectations of the investors in a closely observed phase -3 study. The Novo share fell by more than 20% last year, and people feared that things would get worse if the company published the result of the fourth quarter and its prospects of 2025 on Wednesday.
Instead, Novo exceeded the fourth quarter's expectations and provided a forecast for sales growth between 16% and 24%, according to the 20% Wall Street. Novo's share rose by more than 4%on Wednesday.
In an interview with CNBC, Novo Chief Executive Officer Lars Fruergaard Jorgensen has dropped concerns that Novo falls behind Lilly.
“We are quite confident that we are moving to the year and we deliver more and more of the starter cans, we can see a nice step in our volume and serve more and more patients,” said Jorgensen. “And the instructions that we have given for this year testifies that a significant ramp is based in our business. So we are very confident that we have asked on the market, and also in our ability to in this market to supply and compete.
Jonathan Raa | Nurphoto | Getty pictures
People who start away with the lowest dose – or the starter dose – then work on stronger formulations so that their bodies can get used to the medication. Sometimes Novo has limited the amount of starter cans it sent because it had to fight To make enough of the drug and wanted to make sure that people who were already in the medication could stay in it.
The sales advice from Novo 2025 implies an increase in the number of patients by 30%, which takes one of the GLP-1 medication of the company like Ozempic, the company announced with its profit connection.
The company also tried to calm investors about the effectiveness of Cagrisema. Jorgensen said that some people had decreased very quickly, and another group has decreased continuously and showed no signs that they stop until the end of the experiment so that they may need longer treatment.
“I am very confident in the effectiveness of the biology that we have here,” he said.
People observe earlier treatment earlier-amycletin-noch. This experimental medicine recently showed promising results in a phase 1b/2a study.
Jorgensen said Novo talked to the FDA about switching three attempts directly to a phase.
